CWM
MRNA icon

CarsonAllaria Wealth Management’s Moderna MRNA Stock Holding History

CarsonAllaria Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-234
Closed -$6.46K – 238
2025
Q2 		$6.46K Hold
234
– – ﹤0.01% 274
2025
Q1 		$6.63K Buy
234
+38
+19% +$1.35K ﹤0.01% 278
2024
Q4 		$8.15K Buy
196
+84
+75% +$4.01K ﹤0.01% 260
2024
Q3 		$7.49K Sell
112
-61
-35% -$5.6K ﹤0.01% 281
2024
Q2 		$20.5K Hold
173
– – 0.01% 192
2024
Q1 		$18.4K Sell
173
-4
-2% -$403 0.01% 196
2023
Q4 		$17.6K Sell
177
-6
-3% -$505 0.01% 181
2023
Q3 		$18.9K Sell
183
-37
-17% -$4.13K 0.02% 165
2023
Q2 		$26.7K Sell
220
-15
-6% -$2K 0.02% 148
2023
Q1 		$36.1K Hold
235
– – 0.03% 124
2022
Q4 		$42K Sell
235
-8
-3% -$1.31K 0.04% 113
2022
Q3 		$29K Sell
243
-9
-4% -$1.37K 0.03% 128
2022
Q2 		$36K Buy
252
+17
+7% +$2.43K 0.03% 119
2022
Q1 		$40K Buy
235
+7
+3% +$1.18K 0.04% 118
2021
Q4 		$58K Buy
+228
New +$66.7K 0.05% 111

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CarsonAllaria Wealth Management's MRNA Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 234 shares — an estimated $6.46K sold.

CarsonAllaria Wealth Management first reported a position in MRNA in Q4 2021 and held it in 15 quarters. The position peaked at $58K in Q4 2021. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • CarsonAllaria Wealth Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • CarsonAllaria Wealth Management sold 234 Moderna shares in Q3 2025, an estimated $6.46K.
  • CarsonAllaria Wealth Management first reported a position in Moderna in Q4 2021 and held it in 15 quarters.
  • CarsonAllaria Wealth Management's Moderna position peaked at $58K in Q4 2021.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.